Zobrazeno 1 - 10
of 47
pro vyhledávání: '"Shahrooz Eshaghian"'
Autor:
Samuel D. Stampfer, Sean Bujarski, Marissa‐Skye Goldwater, Scott Jew, Bernard Regidor, Haiming Chen, Ning Xu, Mingjie Li, Eddie Fung, Regina Swift, Bethany Beatty, Shahrooz Eshaghian, James R. Berenson
Publikováno v:
Cancer Reports, Vol 6, Iss 5, Pp n/a-n/a (2023)
Abstract Background Multiple myeloma (MM) patients have variable responses to mRNA vaccination to COVID‐19. Little is known regarding their vaccine‐induced antibody levels over time. Methods We monitored spike IgG antibody levels over 24 weeks am
Externí odkaz:
https://doaj.org/article/bb9ad0d3dbb24064b8f3ae5394852ffe
Autor:
Samuel D. Stampfer, Marissa-Skye Goldwater, Sean Bujarski, Bernard Regidor, Wenjuan Zhang, Aaron J. Feinstein, Regina Swift, Shahrooz Eshaghian, Eric Vail, James R. Berenson
Publikováno v:
Clinical Infection in Practice, Vol 13, Iss , Pp 100130- (2022)
Background: Patients with multiple myeloma have unpredictable responses to vaccination for COVID-19. Anti-spike antibody levels can determine which patients develop antibodies at levels similar to healthy controls, and are a known correlate of protec
Externí odkaz:
https://doaj.org/article/8dfc4853844b41d6a5030489015e8d31
Autor:
Jonathan Afari, Tanya M. Spektor, Carley Turner, Alexa Cohen, Alberto Bessudo, Haresh Jhangiani, Nashat Gabrail, Samir Kubba, Jeffrey D. Neidhart, Shahrooz Eshaghian, Regina A. Swift, Benjamin M. Eades, Clara Kim, Susanna Kim, Robert Vescio, James R. Berenson
Publikováno v:
Experimental Hematology. 114:54-60
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea645f5314db051d9e48ec22a47ab4f0
https://doi.org/10.1016/j.exphem.2022.07.303
https://doi.org/10.1016/j.exphem.2022.07.303
Autor:
Robert Vescio, Stephen Lim, Robert A. Moss, Laura Stampleman, Shahrooz Eshaghian, Gary Schwartz, Regina A. Swift, Benjamin M. Eades, Matthew Ghermezi, Armando Sanchez, Carley Turner, Daisy Martinez, Tanya M. Spektor, Jennifer To, James R. Berenson
Purpose:Ruxolitinib with lenalidomide and dexamethasone shows antimyeloma effects in vitro and in vivo. MUC1 leads to lenalidomide resistance in multiple myeloma cells, and ruxolitinib blocks its expression. Thus, ruxolitinib may restore sensitivity
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10e76ed63cd0dafbb82ebf104a650b78
https://doi.org/10.1158/1078-0432.c.6527949.v1
https://doi.org/10.1158/1078-0432.c.6527949.v1
Autor:
Robert Vescio, Stephen Lim, Robert A. Moss, Laura Stampleman, Shahrooz Eshaghian, Gary Schwartz, Regina A. Swift, Benjamin M. Eades, Matthew Ghermezi, Armando Sanchez, Carley Turner, Daisy Martinez, Tanya M. Spektor, Jennifer To, James R. Berenson
Supplementary Tables and Figure
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05cd84f7cfd3df3dadccb9334d5f61f2
https://doi.org/10.1158/1078-0432.22471611
https://doi.org/10.1158/1078-0432.22471611
Autor:
Shahrooz Eshaghian, James R. Berenson, Gary T. Schwartz, Stephen Lim, Robert Vescio, Benjamin Eades, Tanya M. Spektor, Matthew Ghermezi, David Yashar, Daisy Martinez, Regina A. Swift
Publikováno v:
Leukemia & Lymphoma. 63:975-983
High-risk multiple myeloma (MM) continues to have a poor prognosis and remains a therapeutic challenge. This phase 2 study evaluated the efficacy and safety of elotuzumab in combination with pomalidomide, carfilzomib, and low-dose dexamethasone for p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::acd12ada91b8a914db3c9b66974ab218
https://doi.org/10.1080/10428194.2021.2005044
https://doi.org/10.1080/10428194.2021.2005044
Autor:
David R. Gandara, Thomas E. Stinchcombe, Caroline E. McCoach, Alison M. Schram, Emilio Paul Araujo-Mino, Timmy Nguyen, Jorge Nieva, Aditya Bardia, Lesli A. Kiedrowski, Alessandro Russo, Janakiraman Subramanian, David S. Hong, Christian Rolfo, Kristin Price, Alexander Drilon, Afshin Dowlati, Jessica J. Lin, Stephen V. Liu, Michael A. Morse, Deepa Sashital, Mohammad Mobayed, Neelima Vidula, Shahrooz Eshaghian, Scott N. Gettinger, Sarah B. Goldberg
Publikováno v:
Br J Cancer
Background Activating fusions of the NTRK1, NTRK2 and NTRK3 genes are drivers of carcinogenesis and proliferation across a broad range of tumour types in both adult and paediatric patients. Recently, the FDA granted tumour-agnostic approvals of TRK i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8da4c2e2e32d7efa4108cc5b021b9a40
https://doi.org/10.1038/s41416-021-01536-1
https://doi.org/10.1038/s41416-021-01536-1
Autor:
Samuel D. Stampfer, Sean Bujarski, Merissa-Skye Goldwater, Scott Jew, Bernard Sean Regidor, Haiming Chen, Ning Xu, Mingjie Li, Eddie Fung, Regina A. Swift, Bethany Beatty, Shahrooz Eshaghian, James Berenson, MD, Inc.
Background Multiple myeloma (MM) patients have variable responses to mRNA vaccination to COVID-19. Little is known regarding their vaccine-induced antibody levels over time. Methods We monitored spike IgG antibody levels over 24 weeks among a subset
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8caf96a4dab00638bd9e356c41e2aa0f
https://doi.org/10.22541/au.166879031.16384547/v1
https://doi.org/10.22541/au.166879031.16384547/v1
Autor:
Samuel D. Stampfer, Aaron J. Feinstein, Haiming Chen, Tracy Green, Scott Jew, Tanya M. Spektor, Sean Bujarski, Marissa-Skye Goldwater, Shahrooz Eshaghian, Elias Aquino, Ning Xu, Bernard Regidor, James R. Berenson, David Daniely, Mingjie Li, Eddie Fung, Kurt Preugschat, Regina A. Swift
Publikováno v:
Leukemia
Multiple myeloma (MM) patients are at higher risk for severe COVID-19. Their mRNA vaccination response against SARS-CoV-2 is unknown. Thus, we analyzed responses to mRNA vaccination against COVID-19 among these patients. Using an ELISA-based assay th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9ad4dd496bd573efb26ee011f9be07a
https://doi.org/10.1038/s41375-021-01354-7
https://doi.org/10.1038/s41375-021-01354-7
Autor:
James R. Berenson, Clara Kim, Sean Bujarski, Jennifer To, Tanya M. Spektor, Daisy Martinez, Carley Turner, Matthew Ghermezi, Benjamin M. Eades, Regina A. Swift, Gary Schwartz, Shahrooz Eshaghian, Robert A. Moss, Stephen Lim, Robert Vescio
Publikováno v:
Hematological oncologyREFERENCES. 40(5)
Ruxolitinib with lenalidomide and dexamethasone shows anti-myeloma effects in vitro and in vivo. MUC1 leads to lenalidomide resistance in multiple myeloma (MM) cells, and ruxolitinib blocks its expression. Thus, ruxolitinib may restore sensitivity to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3c24e709c846d03c6fe392792abcafc
https://pubmed.ncbi.nlm.nih.gov/35946431
https://pubmed.ncbi.nlm.nih.gov/35946431